Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10159759 | RADIOMEDIX | Pet tracer for imaging of neuroendocrine tumors |
Aug, 2032
(8 years from now) | |
US10383961 | RADIOMEDIX | PET tracer for imaging of neuroendocrine tumors |
Aug, 2032
(8 years from now) | |
US11160888 | RADIOMEDIX | PET tracer for imaging of neuroendocrine tumors |
Aug, 2032
(8 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 3, 2025 |
Orphan Drug Exclusivity (ODE) | Sep 3, 2027 |
Drugs and Companies using COPPER DOTATATE CU-64 ingredient
NCE-1 date: 2024-09-03
Market Authorisation Date: 03 September, 2020
Treatment: Use of cu-64 dotatate with positron emission tomography (pet) for localization of somatostatin receptor positive neuroendocrine tumors (nets) in adult patients
Dosage: SOLUTION;INTRAVENOUS